Johnson & Johnson will stop offering voluntary 340B pricing on Janssen brand orphan drugs to hundreds of rural hospitals at the end of this year.
News Alert: Johnson & Johnson Ending Voluntary 340B Pricing on Orphan Drugs to Rural and Free-standing Cancer Hospitals
Drug manufacturer Johnson & Johnson will stop offering voluntary 340B pricing on Janssen brand orphan drugs to hundreds of rural hospitals at the end of this year. J&J’s decision also applies to the three free-standing cancer hospitals enrolled in 340B.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.